Prescription-drug ad may lack fair balance if side-effect prominence trails efficacy

DisputedwarningBinding lawRaised as a question — a person decides

Rule

A prescription-drug advertisement subject to section 502(n) of the act — which 202.1(l)(1) states include journal, magazine, other periodical, newspaper, radio, television and telephone advertisements — may be false, lacking in fair balance, or otherwise misleading if it fails to present side-effect and contraindication information with a prominence and readability reasonably comparable to the presentation of effectiveness information. Under 202.1(l)(2), brochures, booklets, mailing pieces, detailing pieces, file cards, bulletins, exhibits, literature, reprints and similar items disseminated by or on behalf of the manufacturer are determined to be labeling under section 201(m) of the act rather than advertisements subject to section 502(n); paragraph (e)(7)(viii) is addressed to advertisements, but other requirements applicable to promotional labeling are not displaced by this classification.

Check

For a piece that is an advertisement subject to section 502(n) (which 202.1(l)(1) states include journal, magazine, other periodical, newspaper, radio, television and telephone advertisements), compare the risk section (side effects/contraindications) against the effectiveness section for every implementing factor the regulation lists: typography (font size/weight), layout, contrast, headlines, paragraphing, white space, and any other technique apt to achieve emphasis. Indicators that the presentation may not be reasonably comparable — and therefore that the advertisement may be lacking in fair balance — include smaller or lighter type, denser/uninterrupted paragraphing, lower contrast, absence of a headline or callout, or cramped spacing for risk information relative to benefit claims; the assessment is made across all implementing factors taken together, not on any single factor in isolation. Note that brochures, detailing pieces, mailers, and similar items disseminated by or on behalf of the manufacturer are treated as labeling under 202.1(l)(2) rather than as advertisements under this paragraph, though they remain subject to other applicable promotional-labeling requirements.

Escalate when

Escalate whenever the visual/layout comparison between risk and benefit sections is not clearly equivalent on one or more implementing factors (typography, layout, contrast, headlines, paragraphing, white space) and a qualitative judgment is needed, considering all factors together, on whether the disparity is enough to constitute lack of fair balance; also escalate whenever it is unclear whether the piece is an advertisement subject to section 502(n) versus labeling under 202.1(l)(2).

Where this comes from

21 CFR 202.1(e)(7)(viii). The highlighted words are quoted exactly; a script confirms they appear in the source before the rule can be published.

…hout disclosing that the claims are not established and the limitations of the supporting evidence. (vii) Fails to provide sufficient emphasis for the information relating to side effects and contraindications, when such information is contained in a distinct part of an advertisement, because of repetition or other emphasis in that part of the advertisement of claims for effectiveness or safety of the drug. (viii) Fails to present information relating to side effects and contraindications with a prominence and readability reasonably comparable with the presentation of information relating to effectiveness of the drug, taking into account all implementing factors such as typography, layout, contrast, headlines, paragraphing, white space, and any other techniques apt to achieve emphasis. (ix) Fails to provide adequate emphasis (for example, by the use of color scheme, borders, headlines, or copy that extends across the gutter) for the fact that two facing pages are part of the same advertisement when one page contains information relating to side effects and contraindications. (x) In an advertisement promoting use of the drug in a selected class of patients (for example, geriatric patients or depr…

Open the original at these words on ecfr.gov ↗Read our full copy →

Document: 21 CFR 202.1
Version: 2026-09-16 — the link above is pinned to this date, so it shows the text as it stood then
Retrieved: 2026-09-21 from www.ecfr.gov
Fingerprint: a542640a872b3f2702d549e8…

Applies when

Naturepromotional

Communication typeadvertisement

How this rule was checked

The verifier and drafter could not agree. Waiting for a human decision — not used in reviews.

Drafted
claude-sonnet-5 · 2026-09-21
Independent verification — revise
claude-opus-5 · 2026-09-21
Reviewer's reasons
- The quoted clause is verbatim (e)(7)(viii) and the substance of the rule does follow from it, so the rule is supported in kind; the locator is accurate.
- Overstated on modality: the (e)(7) chapeau in the source reads 'An advertisement MAY BE false, lacking in fair balance, or otherwise misleading ... if it:' — this is a list of conditional indicators, expressly contrasted with the categorical (e)(6) list. The rule renders it as an unconditional 'must be presented with prominence and readability reasonably comparable', which is stronger than the regulation.
- Overstated on scope: applies_when is a bare 'promotional', but 21 CFR 202.1 governs prescription-drug advertisements, and (l)(1)-(l)(2) in the source distinguish covered advertisements (journals, periodicals, newspapers, broadcast) from brochures/detailing pieces/mailers, which are classified as labeling. The rule as written reaches OTC and promotional-labeling materials that this provision does not itself cover.
- Atomic: prominence and readability form a single composite comparability test in the source, and typography, layout, contrast, headlines, paragraphing and white space are enumerated implementing factors of that one test, not independent requirements.
- Determinism correctly set to judgment: 'reasonably comparable' prominence/readability cannot be settled by presence/absence or literal match; the escalation note is apt.
- Authority correctly binding: this is a codified FDA regulation, not guidance.
- Severity 'warning' is defensible and consistent with the 'may be' framing of (e)(7), though the rule text should be brought into line with it.
- Minor completeness note: the check omits 'headlines' and 'paragraphing', which the source lists among the implementing factors alongside those cited.
Revised by the drafter
claude-sonnet-5 · 2026-09-21
Independent verification — revise
claude-opus-5 · 2026-09-21
Reviewer's reasons
- Core proposition is faithful: the quote sits under the heading '(7) Advertisements that may be false, lacking in fair balance, or otherwise misleading. An advertisement may be false... if it:' and the rule statement preserves the regulation's 'may be' framing rather than converting it into a flat prohibition. The seven implementing factors in the check are taken verbatim from the provision.
- Authority 'binding' is correct — 21 CFR 202.1 is a codified regulation, and (k) ties non-compliance to misbranding under 502(n).
- Determinism 'judgment' is correct — 'prominence and readability reasonably comparable' and 'techniques apt to achieve emphasis' turn entirely on impression and relative emphasis, not on presence/absence or literal match. The escalate clause correctly routes borderline layout disparities to a human.
- Locator is right: the quoted sentence is (e)(7)(viii) in the supplied text, and it is distinct from the neighbouring (e)(7)(vii) 'sufficient emphasis' and (e)(7)(ix)-(xii) placement provisions, so the rule is not duplicating them.
- Overstatement 1 — the carve-out sentence goes beyond the source. 202.1(l)(2) says listed items 'are hereby determined to be labeling as defined in section 201(m) of the act'; it does not say that fair-balance obligations cease to apply to them. Stating flatly that 'this specific paragraph does not apply to them' invites a reviewer to clear a detail aid or leave-behind of any risk/benefit prominence disparity, which is a materially unsafe conclusion for a compliance corpus and is not what the cited text establishes.
- Overstatement 2 — 202.1(l)(1) says advertisements subject to 502(n) 'include' journals, magazines, periodicals, newspapers, radio, television and telephone systems. 'Include' is illustrative, not exhaustive, yet both the rule statement ('as defined in 202.1(l)(1)') and the check ('For a piece that qualifies as an advertisement under 202.1(l)(1)') treat the list as a closed definition. That improperly narrows scope and would exclude advertising media not on the 1975-era list.
- Overstatement 3 — the check's 'A violation looks like smaller or lighter type, denser/uninterrupted paragraphing, lower contrast, absence of a headline...' converts any single-factor disparity into a violation. The regulation's standard is 'reasonably comparable' taking into account all implementing factors, and the operative consequence is that the ad 'may be' lacking in fair balance. These are indicators warranting judgment, not per se violations.
- Atomicity is acceptable: the (l)(1)/(l)(2) material functions as a scope precondition to a single substantive prominence test rather than as a second independently checkable requirement.
- applies_when (promotional / advertisement) is justified by the provision's scope and is not inventing limits; severity 'warning' is defensible given the 'may be' framing and the judgment-based test, though the rule statement rather than applies_when carries the prescription-drug limitation.
Revised by the drafter
claude-sonnet-5 · 2026-09-21
Independent verification — revise
claude-opus-5 · 2026-09-21
Reviewer's reasons
- Core requirement is supported: the quote is verbatim from the (e)(7) list in the source, and the rule preserves the chapeau's hedge ('An advertisement may be false, lacking in fair balance, or otherwise misleading... if it'). The rule says 'may be', not 'is prohibited', so it is not overstated.
- Locator 21 CFR 202.1(e)(7)(viii) matches the source text exactly; the quoted sentence is item (viii) in the (e)(7) enumeration.
- determinism 'judgment' is correct: 'prominence and readability reasonably comparable' and 'techniques apt to achieve emphasis' turn on impression and adequacy, not on literal presence/absence.
- authority 'binding' is correct: 21 CFR 202.1 is a codified regulation, and paragraph (k) of the same section links non-compliance to misbranding under section 502(n).
- severity 'warning' is defensible and matches the permissive 'may be' framing of the (e)(7) chapeau; a 'violation' severity would have overstated the paragraph.
- The advertisement-only scope is justified by the source: (e)(7) is headed 'Advertisements that may be false, lacking in fair balance, or otherwise misleading', and (l)(1) and (l)(2) in the source make exactly the advertisement/labeling split the rule describes, including the listed media and the listed brochure/detailing-piece items.
- Unsupported addition: the clause 'other requirements applicable to promotional labeling are not displaced by this classification' (and its restatement in the Check, 'they remain subject to other applicable promotional-labeling requirements') has no basis in the source text. (l)(2) says only that such items 'are hereby determined to be labeling as defined in section 201(m) of the act'; it says nothing about what other requirements do or do not apply.
- The Check correctly renders the regulation's holistic instruction ('taking into account all implementing factors'), stating the assessment is across all factors together rather than any single factor in isolation, so the per-factor enumeration is not an invented pass/fail test.
- applies_when omits the prescription-drug limit. The section is titled 'Prescription-drug advertisements' and the rule statement carries that limit, but the machine-readable conditions ('promotional' + 'advertisement') would fire on non-prescription promotional advertising.
- The rule correctly does not blend in the neighboring paragraph (e)(7)(vii) ('sufficient emphasis... because of repetition'), which is a distinct indicium in the same source; scope stays on the (viii) prominence/readability comparison.
- Atomicity is acceptable: there is one checkable comparison (risk presentation vs. effectiveness presentation), with the labeling classification functioning as a scope gate rather than a second independent requirement.